|19th July 2019||Dmitry Genkin||93,390||Grant/award etc.||$0.00|
|14th March 2018||Dmitry Genkin||29,452||Other acquisition or disposition||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Xenetic Biosciences, Inc. is a biopharmaceutical company, which focuses on progressing XCART, a personalized CAR T platform technology. The company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's tumor cells.